Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "2022"

1420 News Found

JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23


Ube to buy API Corp. from Mitsubishi Chemical
News | August 09, 2022

Ube to buy API Corp. from Mitsubishi Chemical

APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years


FDC Limited reports Q1 FY23 revenue growth of 10%
News | August 08, 2022

FDC Limited reports Q1 FY23 revenue growth of 10%

The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands


Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
News | August 08, 2022

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore


Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr
News | August 04, 2022

Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr

The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.


Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
News | August 04, 2022

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market


Zydus receives final approval from the USFDA for Ivermectin Cream
Drug Approval | August 04, 2022

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.


Merck KGaA posts higher earnings, profits across business segments
News | August 04, 2022

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients


Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
News | August 03, 2022

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.